Chemoresistance and chemosensitization in cholangiocarcinoma

Autoren

Jose JG Marin
Elisa Lozano
Elisa Herraez
Maitane Asensio
Silvia Di Giacomo
Marta R Romero
Oscar Briz
Maria A Serrano
Thomas Efferth
Rocio IR Macias

DOI

10.1016/j.bbadis.2017.06.005

ISSN

0925-4439

Ausgabe der Veröffentlichung

4

Zeitschrift

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Sprache

en

Paginierung

1444 - 1453

Datum der Veröffentlichung

2018

Status

Published

Herausgeber

Elsevier BV

Herausgeber URL

http://dx.doi.org/10.1016/j.bbadis.2017.06.005

Datum der Datenerfassung

2024

Titel

Chemoresistance and chemosensitization in cholangiocarcinoma

Ausgabe der Zeitschrift

1864

Datenquelle: Crossref

Abstract

One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern oncologic pharmacology is to develop novel strategies to overcome CCA chemoresistance either by increasing drug specificity, such as in targeted therapies aimed to inhibit receptors with tyrosine kinase activity, or to increase the amounts of active agents inside CCA cells by enhancing drug uptake or reducing efflux through export pumps. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.

Addresses

Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain. Electronic address: jjgmarin@usal.es.

Autoren

Jose JG Marin
Elisa Lozano
Elisa Herraez
Maitane Asensio
Silvia Di Giacomo
Marta R Romero
Oscar Briz
Maria A Serrano
Thomas Efferth
Thomas Efferth
Rocio IR Macias

DOI

10.1016/j.bbadis.2017.06.005

eISSN

1879-260X

Externe Identifier

PubMed Identifier: 28600147

Funding acknowledgements

CIBERehd: EHD15PI05/2016
Fundación Samuel Solórzano Barruso, Spain: FS/7-2016
Fundación Mutua Madrileña, Spain: Call 2015
Enrico and Enrica Sovena Foundation, Italy:
Spanish Ministry of Economy, Industry and Competitiveness: SAF2016-75197-R
Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain: PI16/00598
German Research Foundation: DFG/GRK 2015/1

Open access

false

ISSN

0925-4439

Ausgabe der Veröffentlichung

4 Pt B

Zeitschrift

Biochimica et biophysica acta. Molecular basis of disease

Schlüsselwörter

Bile Ducts
Epithelial Cells
Humans
Cholangiocarcinoma
Bile Duct Neoplasms
Receptor Protein-Tyrosine Kinases
Antineoplastic Agents
Protein Kinase Inhibitors
Treatment Outcome
Drug Delivery Systems
Drug Resistance, Multiple
Signal Transduction
Apoptosis
Cell Survival
Gene Expression Regulation, Neoplastic
Drug Resistance, Neoplasm
Genetic Therapy

Sprache

eng

Medium

Print-Electronic

Online publication date

2017

Paginierung

1444 - 1453

Datum der Veröffentlichung

2018

Status

Published

Datum der Datenerfassung

2017

Titel

Chemoresistance and chemosensitization in cholangiocarcinoma.

Sub types

Research Support, Non-U.S. Gov't
Review
Journal Article

Ausgabe der Zeitschrift

1864

Datenquelle: Europe PubMed Central

Abstract

One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern oncologic pharmacology is to develop novel strategies to overcome CCA chemoresistance either by increasing drug specificity, such as in targeted therapies aimed to inhibit receptors with tyrosine kinase activity, or to increase the amounts of active agents inside CCA cells by enhancing drug uptake or reducing efflux through export pumps. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.

Date of acceptance

2017

Autoren

Jose JG Marin
Elisa Lozano
Elisa Herraez
Maitane Asensio
Silvia Di Giacomo
Marta R Romero
Oscar Briz
Maria A Serrano
Thomas Efferth
Rocio IR Macias

Autoren-URL

https://www.ncbi.nlm.nih.gov/pubmed/28600147

DOI

10.1016/j.bbadis.2017.06.005

ISSN

0925-4439

Ausgabe der Veröffentlichung

4 Pt B

Zeitschrift

Biochim Biophys Acta Mol Basis Dis

Schlüsselwörter

Biliary cancer
Chemotherapy
Liver cancer
Multidrug resistance
Targeted therapies
Antineoplastic Agents
Apoptosis
Bile Duct Neoplasms
Bile Ducts
Cell Survival
Cholangiocarcinoma
Drug Delivery Systems
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Epithelial Cells
Gene Expression Regulation, Neoplastic
Genetic Therapy
Humans
Protein Kinase Inhibitors
Receptor Protein-Tyrosine Kinases
Signal Transduction
Treatment Outcome

Sprache

eng

Country

Netherlands

Paginierung

1444 - 1453

PII

S0925-4439(17)30200-4

Datum der Veröffentlichung

2018

Status

Published

Datum, an dem der Datensatz öffentlich gemacht wurde

2018

Titel

Chemoresistance and chemosensitization in cholangiocarcinoma.

Sub types

Journal Article
Research Support, Non-U.S. Gov't
Review

Ausgabe der Zeitschrift

1864

Datenquelle: PubMed

Chemoresistance and chemosensitization in cholangiocarcinoma

Werkzeuge